Gyre Therapeutics (GYRE) announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with ...

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a ...

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 25th.Analysts expect Gyre Therapeutics to post earnings ...

Gyre plans to submit an IND application in 2026. For the full year 2025, the Company expects to generate revenues of $118 to $128 million, representing growth of 11.3% to 20.8% over 2024 revenue ...

Earnings per share (EPS) missed analyst estimates by 71%. In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales ...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...